290 related articles for article (PubMed ID: 31164172)
1. Preliminary exploration of clinical factors affecting acute toxicity and quality of life after carbon ion therapy for prostate cancer.
Zhang Y; Li P; Yu Q; Wu S; Chen X; Zhang Q; Fu S
Radiat Oncol; 2019 Jun; 14(1):94. PubMed ID: 31164172
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy.
Akthar AS; Liao C; Eggener SE; Liauw SL
Eur Urol; 2019 Nov; 76(5):686-692. PubMed ID: 31113644
[TBL] [Abstract][Full Text] [Related]
3. Helical tomotherapy for prostate cancer radiation therapy: An audit of early toxicity and quality of life.
Kunheri B; Lakshmi JS; Ravindran GC; Haridas ; Marwaha V
J Cancer Res Ther; 2021; 17(2):366-371. PubMed ID: 34121678
[TBL] [Abstract][Full Text] [Related]
4. Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study.
Parsai S; Juloori A; Sedor G; Reddy CA; Thousand R; Magnelli A; Berglund RK; Stovsky M; Klein EA; Tendulkar RD; Stephans KL
Am J Clin Oncol; 2020 Jul; 43(7):469-476. PubMed ID: 32349020
[TBL] [Abstract][Full Text] [Related]
5. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
[TBL] [Abstract][Full Text] [Related]
6. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
[TBL] [Abstract][Full Text] [Related]
7. Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer.
Pugh TJ; Munsell MF; Choi S; Nguyen QN; Mathai B; Zhu XR; Sahoo N; Gillin M; Johnson JL; Amos RA; Dong L; Mahmood U; Kuban DA; Frank SJ; Hoffman KE; McGuire SE; Lee AK
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):946-53. PubMed ID: 24139077
[TBL] [Abstract][Full Text] [Related]
8. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P
Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907
[TBL] [Abstract][Full Text] [Related]
9. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial.
Hamstra DA; Mariados N; Sylvester J; Shah D; Karsh L; Hudes R; Beyer D; Kurtzman S; Bogart J; Hsi RA; Kos M; Ellis R; Logsdon M; Zimberg S; Forsythe K; Zhang H; Soffen E; Francke P; Mantz C; Rossi P; DeWeese T; Daignault-Newton S; Fischer-Valuck BW; Chundury A; Gay H; Bosch W; Michalski J
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):976-985. PubMed ID: 28209443
[TBL] [Abstract][Full Text] [Related]
10. Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy.
Chennupati SK; Pelizzari CA; Kunnavakkam R; Liauw SL
Cancer Med; 2014 Aug; 3(4):954-61. PubMed ID: 24803087
[TBL] [Abstract][Full Text] [Related]
11. Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.
Dutz A; Agolli L; Baumann M; Troost EGC; Krause M; Hölscher T; Löck S
Acta Oncol; 2019 Jun; 58(6):916-925. PubMed ID: 30882264
[No Abstract] [Full Text] [Related]
12. Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.
Matta R; Chapple CR; Fisch M; Heidenreich A; Herschorn S; Kodama RT; Koontz BF; Murphy DG; Nguyen PL; Nam RK
Eur Urol; 2019 Mar; 75(3):464-476. PubMed ID: 30573316
[TBL] [Abstract][Full Text] [Related]
13. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
Deville C; Jain A; Hwang WT; Woodhouse KD; Both S; Wang S; Gabriel PE; Christodouleas JP; Bekelman J; Tochner Z; Vapiwala N
Acta Oncol; 2018 Nov; 57(11):1506-1514. PubMed ID: 30028227
[TBL] [Abstract][Full Text] [Related]
14. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658
[TBL] [Abstract][Full Text] [Related]
15. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
16. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
17. Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial.
Habl G; Uhl M; Katayama S; Kessel KA; Hatiboglu G; Hadaschik B; Edler L; Tichy D; Ellerbrock M; Haberer T; Wolf MB; Schlemmer HP; Debus J; Herfarth K
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):435-443. PubMed ID: 27084659
[TBL] [Abstract][Full Text] [Related]
18. Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials.
Henderson RH; Hoppe BS; Marcus RB; Mendenhall WM; Nichols RC; Li Z; Su Z; Morris CG; Williams CR; Costa J; Mendenhall NP
Acta Oncol; 2013 Apr; 52(3):463-9. PubMed ID: 23477359
[TBL] [Abstract][Full Text] [Related]
19. Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity.
Ghadjar P; Jackson A; Spratt DE; Oh JH; Munck af Rosenschöld P; Kollmeier M; Yorke E; Hunt M; Deasy JO; Zelefsky MJ
Eur Urol; 2013 Dec; 64(6):931-8. PubMed ID: 23522772
[TBL] [Abstract][Full Text] [Related]
20. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
